Clinical Trial Update: TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program [Phase 4]

View source ↗

Summary

A Phase 4 safety surveillance trial of TAXUS paclitaxel-eluting stents for de novo coronary lesions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Coronary Artery Disease

Drugs mentioned

• TAXUS Paclitaxel-Eluting Stent (paclitaxel-eluting stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Cardiovascular Disease, de Novo Coronary Lesions | Phase 4 | Status: COMPLETED